VIDEO: APX3330 shows favorable safety profile, fewer adverse effects

ByMichael J. Allingham, MD, PhD

ByDavid W. Mullin

Fact checked byChristine Klimanskis, ELS

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW YORK — In this Healio Video Perspective from the ASRS meeting, Michael J. Allingham, MD, PhD, discusses the safety data from the ZETA-1 phase 2 clinical trial investigating Ocuphire’s APX3330 for the treatment of diabetic retinopathy.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Allingham reports being a paid consultant to Genentech.

Read more about

diabetic retinopathy

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

• Facebook
• Twitter
• LinkedIn
• Email
• Print
• Comment